Chronic Obstructive Pulmonary Disease: A Concise Review - 25/10/11
, Steve Lommatzsch, MD, Brendan Carolan, MD, Barry Make, MDRésumé |
Globally, chronic obstructive pulmonary disease (COPD) is a major cause of significant morbidity and mortality, and is now the third leading cause of death in the United States. Over the past 15 years there has been a surge of bench and translational research regarding the genetics and pathogenesis of COPD, and several large-scale clinical trials have introduced new treatment paradigms for COPD. Current research also demonstrates that COPD is not just a lung disease and that there are several potential extrapulmonary manifestations and comorbidities that should be evaluated and treated when one identifies an individual as having COPD.
Le texte complet de cet article est disponible en PDF.Keywords : Chronic obstructive pulmonary disease, Guidelines, Chronic bronchitis, Emphysema
Plan
| Conflict of Interest: R. Balkissoon: Advisory Boards: Astra Zeneca, Glaxo SmithKline. Speakers Bureau: Astra Zeneca, Glaxo SmithKline, Boehringer Ingelheim, Pfizer, Novartis. |
Vol 95 - N° 6
P. 1125-1141 - novembre 2011 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
